Cryolife (NYSE:CRY) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Cryolife (NYSE:CRY) announced its quarterly earnings results on Thursday. The medical equipment provider reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.01, Fidelity Earnings reports. The company had revenue of $53.77 million during the quarter, compared to analysts’ expectations of $51.30 million. Cryolife had a positive return on equity of 0.98% and a negative net margin of 4.33%.

NYSE:CRY traded up $0.51 during trading hours on Friday, hitting $19.41. 616,255 shares of the company’s stock traded hands, compared to its average volume of 306,316. The firm has a market cap of $732.53 million, a P/E ratio of -64.70 and a beta of 1.37. Cryolife has a 52 week low of $12.63 and a 52 week high of $33.00. The business’s fifty day simple moving average is $19.57 and its two-hundred day simple moving average is $22.63. The company has a quick ratio of 3.66, a current ratio of 4.90 and a debt-to-equity ratio of 0.94.

In other Cryolife news, Director Ronald D. Mccall sold 1,719 shares of Cryolife stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $22.82, for a total transaction of $39,227.58. Following the completion of the sale, the director now owns 127,766 shares of the company’s stock, valued at $2,915,620.12. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 4.70% of the stock is currently owned by company insiders.

CRY has been the subject of several recent research reports. Oppenheimer reiterated a “buy” rating and issued a $25.00 price target on shares of Cryolife in a research report on Thursday. Lake Street Capital lifted their price target on Cryolife from $22.00 to $27.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Zacks Investment Research lowered Cryolife from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. TheStreet lowered Cryolife from a “c-” rating to a “d+” rating in a research note on Friday, July 10th. Finally, Needham & Company LLC assumed coverage on Cryolife in a research note on Tuesday, June 30th. They set a “buy” rating and a $29.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $26.20.

About Cryolife

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Read More: What Factors Can Affect Return on Equity?

Earnings History for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with's FREE daily email newsletter.